

## Grifols is included in the Bloomberg Gender-Equality Index for its commitment to gender equality

- *For the first time, Bloomberg's Gender-Equality Index (GEI) acknowledges Grifols for its commitment and endeavor towards gender equality and wage parity, female leadership and talent promotion, among others*
- *60% of Grifols' workforce is made up of women*
- *Grifols is also part of the Dow Jones Sustainability Index (DJSI), Vigeo Euronext and FTSE4Good*

**Barcelona, January 27, 2021.-** Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare leader in the production of plasma-derived medicines with a proven track record of more than 100 years dedicated to enhancing the health and well-being of people worldwide, is now a part of 2021 Bloomberg Gender-Equality Index (GEI) for the first time ever.

The index recognizes Grifols' commitment to the advancement of women in the labor market through the development of policies and initiatives to promote women's professional careers and greater female representation across the organization. Likewise, it has valued the efforts and progress that the company has been making in recent years to continue advancing in equality and wage parity; increasing female leadership and talent promotion; and applying policies against workplace harassment and campaigns to support women; among others.

For Grifols, its people is one of its main assets and 60% of its employees are women who among them, 98% have permanent contracts.

This recognition reflects Grifols' solid commitment for gender equality, which has always been present in more than one hundred years of history. This proves the merit and talent of female leadership that Grifols has today, while the new Diversity and Inclusion Plan will spark further progress in this area.

This new recognition also bolsters Grifols' efforts to continue contributing to the enforcement of the Sustainable Development Goals (SDG) set by the United Nations, integrated into its strategy, in particular SDG 5 which corresponds to gender equality in the workplace.

The Bloomberg Gender-Equality Index brings transparency to gender-related practices and policies in terms of gender equality and diversity at publicly-listed companies, increasing the quality of information related to environmental, social, governance (ESG) criteria available to capital markets.

In Bloomberg's gender reporting framework, a total of 59 metrics across five dimensions are analyzed: salary equality and gender parity, inclusive culture and integration, female leadership and talent pool, sexual harassment policies, and pro-women brand. The evaluation for 2021 has included 380 companies from 11 different sectors across 44 countries.

This GEI scoring methodology allows investors to assess company performance and compare across industry peer groups.

Grifols has already been listed on the Dow Jones Sustainability Index (DJSI) Europe, Euronext Vigeo Europe 120 and Euronext Vigeo Eurozone 120 since December 2020 and on the sustainability indices FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex since 2018.

---

## Investor contact:

### Investor Relations

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Phone number: +34 93 571 02 21

### Media contacts:

Raquel Lumbreras [Raquel\\_lumbreras@duomocomunicacion.com](mailto:Raquel_lumbreras@duomocomunicacion.com)

Borja Gómez [Borja\\_gomez@duomocomunicacion.com](mailto:Borja_gomez@duomocomunicacion.com)

Duomo Comunicación – **Grifols PR office**

Tel. +34 91 311 92 89 - 91 311 92 90

---

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.